Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Fonar Corporation (FONR)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: FONR (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 1.01% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 3.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 95.29M USD | Price to earnings Ratio 10.64 | 1Y Target Price - |
Price to earnings Ratio 10.64 | 1Y Target Price - | ||
Volume (30-day avg) 10924 | Beta 1.19 | 52 Weeks Range 14.05 - 24.05 | Updated Date 01/12/2025 |
52 Weeks Range 14.05 - 24.05 | Updated Date 01/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.27% | Operating Margin (TTM) 5.14% |
Management Effectiveness
Return on Assets (TTM) 4.98% | Return on Equity (TTM) 9.17% |
Valuation
Trailing PE 10.64 | Forward PE - | Enterprise Value 83667576 | Price to Sales(TTM) 0.94 |
Enterprise Value 83667576 | Price to Sales(TTM) 0.94 | ||
Enterprise Value to Revenue 0.82 | Enterprise Value to EBITDA 3.18 | Shares Outstanding 6271660 | Shares Floating 5846309 |
Shares Outstanding 6271660 | Shares Floating 5846309 | ||
Percent Insiders 2.42 | Percent Institutions 49.78 |
AI Summary
Fonar Corporation: A Comprehensive Overview
Company Profile
History and Background
Founded in 1978 by Raymond Damadian, Fonar Corporation is a medical device company specializing in Magnetic Resonance Imaging (MRI) technology. Dr. Damadian pioneered the MRI concept, and Fonar has since become a leading manufacturer of high-field open MRI scanners.
Fonar's journey hasn't been smooth. The company faced financial difficulties in the 1990s and 2000s, but it has emerged as a key player in the open MRI market. Today, Fonar focuses on developing innovative and affordable MRI technology for various medical applications.
Core Business Areas
Fonar's core business areas are:
- Manufacturing and selling open MRI scanners: These scanners offer a more comfortable experience for patients, particularly those with claustrophobia, as they are open on all sides.
- Developing new MRI technologies: Fonar continuously invests in research and development to enhance the capabilities and affordability of its MRI systems.
- Providing service and support: Fonar offers comprehensive service and support to its customers, ensuring optimal performance and uptime of their MRI scanners.
Leadership and Corporate Structure
The current leadership team of Fonar Corporation includes:
- Raymond V. Damadian, Ph.D.: Founder, Chairman, and Chief Visionary Officer
- Thomas R. Horn: President and Chief Executive Officer
- David A. DeMeo, CPA: Chief Financial Officer
Fonar operates under a traditional corporate structure with a Board of Directors overseeing the company's strategic direction.
Top Products and Market Share
Top Products
Fonar's top products include:
- Upright MRI Scanner: This scanner allows patients to be scanned in a standing position, which is beneficial for specific medical conditions.
- Open MRI Scanner: This scanner provides a more comfortable experience for patients with claustrophobia.
- 7 Tesla MRI Scanner: This high-field scanner offers superior image quality and faster scanning times.
Market Share
Fonar holds a significant market share in the open MRI segment, particularly in the United States. However, the overall MRI market is dominated by larger players like GE Healthcare, Siemens Healthineers, and Philips.
Competitive Landscape
Fonar faces competition from major medical device companies in the MRI market. While Fonar excels in open MRI technology, its competitors offer a wider range of MRI systems and advanced imaging capabilities.
Total Addressable Market
The global MRI market was valued at USD 7.8 billion in 2022 and is expected to reach USD 12.5 billion by 2028, growing at a CAGR of 8.5%. The increasing demand for early disease diagnosis and the growing prevalence of chronic diseases are driving this market growth.
Financial Performance
Fonar's recent financial performance has been mixed. The company has reported losses in recent years, but revenue has been increasing.
Key financial metrics as of October 27, 2023:
- Revenue (TTM): $34.5 million
- Net Loss (TTM): $13.6 million
- EPS (TTM): -$0.45
- Cash and Equivalents: $14.7 million
- Debt (Total): $22.8 million
Dividends and Shareholder Returns
Fonar does not currently pay dividends. Since the company is not profitable, it is unlikely to initiate dividend payments in the near future.
Growth Trajectory
Fonar's historical growth has been volatile, with periods of significant revenue increases followed by declines. The company's future growth prospects depend on its ability to successfully launch new products, expand its market share, and improve profitability.
Market Dynamics
The MRI market is characterized by:
- Technological advancements: Continuous innovation in MRI technology is driving the development of faster, more powerful, and more affordable scanners.
- Increased demand for early diagnosis: The rising prevalence of chronic diseases is increasing the demand for early diagnosis, which is driving the adoption of MRI technology.
- Competitive landscape: The MRI market is dominated by a few large players, but there are also several smaller players, including Fonar, focusing on niche segments.
Competitors
Fonar's main competitors in the MRI market include:
- GE Healthcare (GE)
- Siemens Healthineers (SHG)
- Philips (PHG)
- Hitachi Medical Systems (Hit)
- Toshiba Medical Systems (Tos)
Potential Challenges and Opportunities
Challenges
- Intense competition from larger players with broader product offerings and advanced technologies.
- Maintaining profitability in a competitive market with pressure on pricing.
- Adapting to rapid technological advancements and keeping up with the latest innovations.
Opportunities
- Growing demand for MRI technology in emerging markets.
- Expanding into new market segments, such as veterinary imaging and interventional procedures.
- Developing new and innovative MRI technologies to differentiate itself from competitors.
Recent Acquisitions
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 1987-01-01 | Chairman, President, CEO & Treasurer Mr. Timothy R. Damadian M.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 520 | Website https://www.fonar.com |
Full time employees 520 | Website https://www.fonar.com |
FONAR Corporation, together with its subsidiaries, engages in the designing, manufacturing, and selling magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases, abnormalities, other medical conditions, and injuries in the United States. It operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. The company offers Upright MRI scanner, allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. It also provides non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. In addition, the company owns and operates diagnostic imaging facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1978 and is based in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.